Orbimed Advisors LLC X4 Pharmaceuticals, Inc Transaction History

Orbimed Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$0.24 - $0.81 $85,680 - $289,170	-357,000 Reduced 5.0%	6,776,515 $1.63 Million
Q2 2023 Aug 14, 2023	BUY	$0.82 - $2.49 $1.08 Million - $3.28 Million	1,315,789 Added 22.62%	7,133,515 $13.8 Million
Q4 2022 Feb 14, 2023	BUY	$0.69 - $2.21 $545,727 - $1.75 Million	790,909 Added 15.73%	5,817,726 $5.76 Million
Q3 2022 Nov 14, 2022	BUY	$0.89 - $1.71 $3.25 Million - $6.25 Million	3,652,968 Added 265.89%	5,026,817 $8.6 Million
Q1 2021 May 17, 2021	BUY	$6.63 - $10.28 $1.91 Million - $2.95 Million	287,356 Added 26.45%	1,373,849 $11.8 Million
Q4 2019 Feb 14, 2020	BUY	$9.93 - $14.33 $1.49 Million - $2.15 Million	150,000 Added 16.02%	1,086,493 $11.6 Million
Q2 2019 Aug 14, 2019	BUY	$12.57 - $21.67 $7.86 Million - $13.5 Million	625,000 Added 200.65%	936,493 $14 Million
Q1 2019 May 15, 2019	BUY	$15.19 - $22.98 $4.73 Million - $7.16 Million	311,493 New	311,493 $5.42 Million

22.3M

45.8K

Ticker XFOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,646,096
Market Cap $177M
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.